Azurity, Takeda & Arbor v. Teva: EDARBYCLOR Patent Dispute Dismissed
Three pharmaceutical plaintiffs — Azurity Pharmaceuticals, Takeda Pharmaceutical, and Arbor Pharmaceuticals — brought a patent infringement action against Teva over EDARBYCLOR, an azilsartan medoxomil/chlorthalidone combination antihypertensive tablet. The case closed after 228 days when the parties stipulated to dismiss all claims without prejudice under Rule 41(a)(1)(A)(ii), with each side bearing its own costs.
EDARBYCLOR combination tablet patents: a three-plaintiff ANDA battle that ended quietly
Filed on 29 September 2023 in the Delaware District Court before Judge Maryellen Noreika, this Hatch-Waxman infringement action was brought by Azurity Pharmaceuticals, Takeda Pharmaceutical Company Limited, and Arbor Pharmaceuticals against Teva Pharmaceutical Industries. The asserted patents — US9169238B2, US9066936B2, and US9387249B2 — cover EDARBYCLOR, a fixed-dose combination oral tablet containing 40 mg azilsartan medoxomil and either 25 mg or 12.5 mg chlorthalidone, used in the treatment of hypertension.
The case closed on 14 May 2024 when the parties filed a stipulated dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). All claims, counterclaims, and defenses were dismissed in their entirety without prejudice, meaning the plaintiffs retain the right to re-file on the same patents and product. The stipulation also provided that each party would bear its own attorneys’ fees and costs, suggesting no side extracted a financial concession as a condition of exit.
At 228 days, the case resolved well before any trial date, consistent with the parties having reached a licensing arrangement, consent judgment, or commercial understanding that made continued litigation unnecessary. The without-prejudice dismissal is notable: it preserves all plaintiffs’ enforcement rights against Teva on these patents, and the public record does not disclose any settlement terms, consent decree, or market-entry date agreement. Whether Teva obtained a license or deferred its ANDA launch remains unknown from the docket alone.
Filing to Dismissed with Prejudice in 228 days
228 days — resolved before trial, consistent with early settlement or negotiated resolution
Dismissed without prejudice: what the stipulation means for both sides
Rule 41(a)(1)(A)(ii) stipulated dismissal — no merits adjudication
A Rule 41(a)(1)(A)(ii) dismissal is a voluntary, bilateral exit: both parties sign the stipulation and the court need not approve it. Crucially, ‘without prejudice’ means the case is terminated procedurally, not on the merits. No patent has been held valid, invalid, infringed, or not infringed. The plaintiffs retain the full right to re-assert all three patents against Teva in a new action if circumstances — such as a commercial launch — warrant it.
No merits rulingPlaintiffs keep all enforcement rights intact
Because the dismissal is without prejudice, Azurity, Takeda, and Arbor have not surrendered any patent rights. US9169238B2, US9066936B2, and US9387249B2 remain in force and unlitigated on the merits. If Teva proceeds toward commercial launch without a license, plaintiffs can re-file immediately. The absence of a with-prejudice dismissal or invalidity stipulation is a meaningful protection for the brand-side coalition.
Patent rights preservedTeva exits without invalidity finding — but no license confirmed publicly
Teva obtained a clean exit with no adverse merits ruling, no damages, and no injunction on record. However, the without-prejudice nature of the dismissal means Teva cannot treat this as a cleared path to launch. If Teva’s ANDA approval proceeds, the risk of re-litigation against all three patents remains live. The public record does not confirm whether Teva secured a license or agreed to a market-entry date as part of any undisclosed settlement.
Launch risk remainsEDARBYCLOR generic entry timeline remains commercially uncertain
The quiet, cost-neutral exit of a multi-plaintiff Hatch-Waxman action often signals a background licensing or authorised-generic arrangement, though this cannot be confirmed from the docket. For payers, prescribers, and competing ANDA filers, the without-prejudice dismissal without any public consent decree leaves EDARBYCLOR’s generic entry timeline opaque. Competitor ANDA filers should note that the three asserted patents remain enforceable and unlitigated on the merits.
Generic timeline unclearFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Azurity Pharmaceuticals, Inc. | Company | Pharmaceutical patent holders — collectively asserting US9169238B2, US9066936B2, and US9387249B2Search in Eureka ↗ |
| Co-Plaintiff | Takeda Pharmaceutical Company Limited | Company | Search in Eureka ↗ |
| Co-Plaintiff | Arbor Pharmaceuticals, LLC | Company | Search in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Teva Pharmaceutical Industries, Ltd. — generic drug manufacturer, ANDA filer for EDARBYCLORSearch in Eureka ↗ |
| Co-Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Maliheh Zare | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sarah E. Spencer | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Danielle Z. Mills | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Elana B. Araj | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Jonathan D. Ball | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Karen Elizabeth Keller | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Kathryn E. Albanese | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Nathan Roger Hoeschen | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Scott J. Bornstein | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant law firm | Shaw Keller LLP | Law Firm | Representing Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation expressly invokes Rule 41(a)(1)(A)(ii) and confirms dismissal ‘without prejudice’ of all claims, counterclaims, and defenses in their entirety. This phrasing is legally significant: no patent claim has been adjudicated, no invalidity or non-infringement finding was made, and no injunction or damages were awarded. The equal cost-bearing provision suggests neither party extracted a litigation concession. The without-prejudice designation keeps all enforcement options alive for the plaintiff coalition.
US9169238B2, US9066936B2 & US9387249B2 — EDARBYCLOR azilsartan/chlorthalidone combination
The three asserted patents — US9169238B2, US9066936B2, and US9387249B2 — collectively cover the compound, formulation, and methods associated with EDARBYCLOR, Takeda’s fixed-dose combination antihypertensive product containing azilsartan medoxomil (an angiotensin II receptor blocker) paired with chlorthalidone (a thiazide-like diuretic). The application numbers trace to filings in the 2009–2010 timeframe, situating these patents in the era of originator combination cardiovascular drug development. Together, they form a layered patent estate designed to protect the product across multiple dimensions of IP.
For the pharmaceutical sector, a three-patent stack covering compound, formulation, and method claims is a recognised enforcement architecture in Hatch-Waxman litigation. Each layer independently triggers the 30-month stay on ANDA approval, providing the brand-side coalition with extended market exclusivity. Competitors developing generic azilsartan medoxomil/chlorthalidone combinations — or related angiotensin receptor blocker/diuretic fixed-dose products — must carefully assess the claim scope of all three patents before filing paragraph IV certifications or initiating commercial development.
Should you run an FTO against US9169238B2, US9066936B2, and US9387249B2?
Any organisation developing, manufacturing, or seeking ANDA approval for an azilsartan medoxomil and chlorthalidone fixed-dose combination tablet should treat these three patents as live enforcement risks. The without-prejudice dismissal in this case means no invalidity finding exists in the public record. R&D teams working on combination antihypertensive formulations — including ARB/thiazide diuretic products with structural or formulation similarities — should conduct a proactive FTO analysis before committing to clinical development or regulatory filing.
PatSnap Eureka’s FTO Search Agent enables IP and R&D teams to map claim scope across all three asserted patents simultaneously, identify prosecution history estoppel, and surface prior art that may support design-around or invalidity strategies. Eureka’s AI-assisted claim mapping can flag overlap with your specific formulation parameters — active ingredient ratios, tablet architecture, and dosing methods — and generate a risk-ranked landscape report to inform go/no-go decisions before an ANDA paragraph IV certification is filed.
Run a freedom-to-operate analysis on US9169238B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman cases: azilsartan and ARB combination drug patents in Delaware
Browse related ANDA infringement actions involving antihypertensive combination drug patents litigated in Delaware District Court by Takeda, Azurity, and Arbor.
What this case signals for the antihypertensive combination drug IP landscape
A three-plaintiff coalition, three blocking patents, and a cost-neutral exit — this case offers a textbook look at Hatch-Waxman leverage dynamics.
Multi-plaintiff patent stacking amplifies Hatch-Waxman leverage against generics
Assembling Azurity, Takeda, and Arbor as co-plaintiffs across three patents meant Teva faced coordinated litigation exposure on a fixed-dose combination product. This coalition structure — common in branded pharmaceutical IP enforcement — raises the cost and complexity for any ANDA filer, and typically signals that the brand side is prepared to litigate aggressively to protect the product.
Without-prejudice exit is not a green light for generic launch
IP professionals and ANDA filers monitoring EDARBYCLOR should note that all three patents remain assertable. A without-prejudice dismissal creates no estoppel, no license by implication, and no invalidity shield. Any generic entrant — Teva or otherwise — that launches without a confirmed license agreement risks immediate re-litigation on US9169238B2, US9066936B2, and US9387249B2.
Azurity v Teva — key questions answered
The without-prejudice dismissal under Rule 41(a)(1)(A)(ii) means all claims were terminated with no merits ruling. Azurity, Takeda, and Arbor retain full rights to re-assert US9169238B2, US9066936B2, and US9387249B2 against Teva. No invalidity, non-infringement, or unenforceability finding was entered. The patents remain in force and fully enforceable.
Three patents were asserted: US9169238B2, US9066936B2, and US9387249B2, all covering aspects of EDARBYCLOR — a fixed-dose combination oral tablet containing 40 mg azilsartan medoxomil and either 12.5 mg or 25 mg chlorthalidone. The patents relate to the compound, formulation, and associated methods for this antihypertensive combination product.
Rule 41(a)(1)(A)(ii) permits voluntary dismissal by filing a stipulation signed by all parties, requiring no court order. It is commonly used in Hatch-Waxman litigation when parties reach a confidential resolution — such as a licensing agreement or consent judgment — and wish to exit the litigation cleanly. The without-prejudice qualifier preserves the plaintiffs’ right to re-file if the underlying commercial agreement breaks down.
The public docket does not confirm any licensing arrangement. The stipulated dismissal is silent on commercial terms. In Hatch-Waxman practice, cost-neutral without-prejudice dismissals before trial are consistent with a confidential settlement that may include a license or authorised-generic agreement, but this cannot be confirmed from the available public record alone.
No. A without-prejudice dismissal creates no collateral estoppel, no invalidity finding, and no license by implication for third parties. US9169238B2, US9066936B2, and US9387249B2 remain fully assertable. Any competitor ANDA filer would face the same litigation exposure from the plaintiff coalition that Teva faced, and should conduct independent FTO and invalidity analysis before launch.
PatSnap Eureka searches patents and litigation data to answer instantly.